TRIM32 and acute promyelocytic leukemia: Overexpression of TRIM32 in the human promyelogenous leukemic cell line HL60 suppresses cellular proliferation and induces granulocytic differentiation, implying that TRIM32 may be a potentially therapeutic target for APL [16].